The Lancet publishes Lundbeck Vyepti study

The firm’s study of migraine treatment Vyepti has been published in the top-ranking medical journal, which is a stamp of approval for Lundbeck’s research quality, according to Head of R&D Johan Luthman.

Photo: Lundbeck / PR

The Lancet, a top-ranking medical journal, has published results from pharmaceutical firm Lundbeck’s Deliver study of migraine drug Vyepeti, the firm announced in a press release on Thursday.

“We are incredibly proud that our clinical research is recognized by the medical and scientific community. The publication of the Deliver results by Lancet Neurology is a clear indication that Lundbeck performs clinical research of the highest quality, and that the results of these efforts are relevant to both clinicians and patients,” says Lundbeck Head of R&D Johan Luthman in the statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs